

Amendments to the Specification:

Title:

Please replace the current Title:

--CHEMICAL COMPOUNDS--

with:


-- *N*-PHENYL-INDAZOLYLACRYLAMIDE DERIVATIVES --.

Page 58-59, Example 29:

Please rewrite Example 29 as:

Example 29

(2E)-*N*-ethyl-3-(1*H*-indazol-3-yl)-*N*-(pyridin-4-ylmethyl)prop-2-enamide



Utilizing the procedure of Example 27 and Scheme 1, Method A, *N*-ethyl-*N*-(pyridin-4-ylmethyl)amine (45 mg, 0.33 mmol) gave *(2E)*-*N*-ethyl-3-(1*H*-indazol-3-yl)-*N*-(pyridin-4-ylmethyl)prop-2-enamide (48 mg) as a tan solid. ¹H NMR (DMSO-*d*₆) δ 13.45 (m, 1 H) 8.53 (m, 2 H) 7.86 (m, 2 H) 7.57 (m, 1 H) 7.40 (m, 2 H) 7.27 (m, 2 H) 7.10 (m, 1 H) 4.78 (m, 2 H) 3.56 (m, 2 H) 1.15 (m, 3 H). MS *m/z* 307 (*M*+1).